Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Get Free Report)'s stock price shot up 6.8% on Monday . The stock traded as high as $37.35 and last traded at $37.28. 287,191 shares traded hands during trading, a decline of 75% from the average session volume of 1,133,233 shares. The stock had previously closed at $34.91.
Analyst Ratings Changes
Several brokerages have weighed in on ALPN. HC Wainwright raised their price objective on Alpine Immune Sciences from $32.00 to $50.00 and gave the company a "buy" rating in a research note on Tuesday, March 19th. Wolfe Research assumed coverage on Alpine Immune Sciences in a report on Thursday, February 15th. They issued an "outperform" rating and a $44.00 price objective for the company. Oppenheimer reissued an "outperform" rating and issued a $44.00 price objective (up previously from $33.00) on shares of Alpine Immune Sciences in a report on Tuesday, March 19th. Morgan Stanley lifted their price objective on Alpine Immune Sciences from $30.00 to $47.00 and gave the stock an "overweight" rating in a report on Tuesday, March 19th. Finally, Wedbush reissued an "outperform" rating and issued a $47.00 price objective on shares of Alpine Immune Sciences in a report on Tuesday, March 19th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $38.86.
Read Our Latest Analysis on ALPN
Alpine Immune Sciences Stock Performance
The stock has a market cap of $2.53 billion, a P/E ratio of -59.22 and a beta of 1.14. The stock has a 50-day moving average price of $34.03 and a 200-day moving average price of $21.75.
Institutional Trading of Alpine Immune Sciences
A number of hedge funds have recently bought and sold shares of ALPN. JPMorgan Chase & Co. lifted its position in Alpine Immune Sciences by 23.4% in the 1st quarter. JPMorgan Chase & Co. now owns 8,947 shares of the biotechnology company's stock worth $80,000 after buying an additional 1,697 shares during the last quarter. Vanguard Group Inc. lifted its position in Alpine Immune Sciences by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 707,598 shares of the biotechnology company's stock worth $6,347,000 after buying an additional 9,844 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Alpine Immune Sciences by 7.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 32,417 shares of the biotechnology company's stock worth $291,000 after buying an additional 2,294 shares during the last quarter. State Street Corp lifted its position in Alpine Immune Sciences by 7.1% in the 1st quarter. State Street Corp now owns 220,621 shares of the biotechnology company's stock worth $1,979,000 after buying an additional 14,609 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Alpine Immune Sciences by 70.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 22,850 shares of the biotechnology company's stock worth $205,000 after buying an additional 9,471 shares during the last quarter. Institutional investors own 75.17% of the company's stock.
About Alpine Immune Sciences
(
Get Free Report)
Alpine Immune Sciences, Inc operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development.
Further Reading
Before you consider Alpine Immune Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpine Immune Sciences wasn't on the list.
While Alpine Immune Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
